4DMedical Crescita futura

Future criteri di controllo 2/6

4DMedical prevede che gli utili e i ricavi cresceranno rispettivamente di 46% e 66.8% all'anno. Si prevede che l'EPS crescerà di 55.3% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -10.5% in 3 anni.

Informazioni chiave

46.0%

Tasso di crescita degli utili

55.3%

Tasso di crescita dell'EPS

Healthcare Services crescita degli utili	20.8%
Tasso di crescita dei ricavi	66.8%
Rendimento futuro del capitale proprio	-10.5%
Copertura analitica	Low
Ultimo aggiornamento	30 Sep 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Here's Why We're Watching 4DMedical's (ASX:4DX) Cash Burn Situation

Sep 21

We're Keeping An Eye On 4DMedical's (ASX:4DX) Cash Burn Rate

May 08

4DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment

Oct 26

Here's Why We're Not At All Concerned With 4DMedical's (ASX:4DX) Cash Burn Situation

Jun 16

Here's Why We're Not Too Worried About 4DMedical's (ASX:4DX) Cash Burn Situation

Jun 05

Is 4DMedical Limited's (ASX:4DX) Shareholder Ownership Skewed Towards Insiders?

Feb 20

Previsioni di crescita degli utili e dei ricavi

ASX:4DX - Stime future degli analisti e dati finanziari passati (AUD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2027	57	-8	-6	-3	3
6/30/2026	36	-14	-12	-9	3
6/30/2025	13	-32	-29	-27	3
6/30/2024	4	-36	-32	-31	N/A
3/31/2024	2	-33	-33	-32	N/A
12/31/2023	1	-31	-34	-32	N/A
9/30/2023	1	-31	-29	-28	N/A
6/30/2023	1	-31	-24	-23	N/A
3/31/2023	1	-30	-19	-18	N/A
12/31/2022	1	-28	-15	-13	N/A
9/30/2022	1	-26	-22	-19	N/A
6/30/2022	1	-25	-29	-25	N/A
3/31/2022	1	-23	-28	-24	N/A
12/31/2021	0	-21	-26	-23	N/A
9/30/2021	0	-21	-21	-19	N/A
6/30/2021	0	-21	-15	-15	N/A
3/31/2021	0	-26	-16	-15	N/A
12/31/2020	0	-30	-16	-15	N/A
9/30/2020	1	-26	-12	-11	N/A
6/30/2020	1	-22	-9	-8	N/A
3/31/2020	2	-16	-8	-7	N/A
12/31/2019	2	-9	-7	-6	N/A
9/30/2019	1	-8	-7	-6	N/A
6/30/2019	1	-6	-7	-6	N/A
6/30/2018	1	-4	-5	-3	N/A
6/30/2017	1	-4	N/A	-2	N/A
12/31/2015	0	-1	N/A	-1	N/A
12/31/2014	0	0	N/A	0	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che 4DX rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che 4DX rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che 4DX rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 4DX ( 66.8% all'anno) crescerà più rapidamente del mercato Australian ( 5.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 4DX ( 66.8% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che 4DX non sarà più redditizia tra 3 anni.

4DMedical Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus revenue estimates fall by 36%

Consensus revenue estimates fall by 20%

No longer forecast to breakeven

Consensus revenue estimates decrease by 22%, EPS upgraded

No longer forecast to breakeven

Price target increased by 21% to AU$1.18

Recent updates

Full year 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

4DMedical Limited, Annual General Meeting, Nov 20, 2024

Here's Why We're Watching 4DMedical's (ASX:4DX) Cash Burn Situation

Consensus revenue estimates fall by 36%

Full year 2024 earnings: EPS and revenues miss analyst expectations

We're Keeping An Eye On 4DMedical's (ASX:4DX) Cash Burn Rate

Consensus revenue estimates fall by 20%

New minor risk - Profitability

No longer forecast to breakeven

Consensus revenue estimates decrease by 22%, EPS upgraded

4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 35 million.

4DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 35 million.

No longer forecast to breakeven

Price target increased by 21% to AU$1.18

4DMedical Receives U.S. FDA Clearance for CT LVAS Lung Function Scanning Software

Forecast to breakeven in 2026

New major risk - Share price stability

4DMedical Limited Announces Resignation of Evonne Collier as a Non-Executive Director, Chair of the Remuneration and Nomination Committee

4DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment

New minor risk - Market cap size

4DMedical Limited Announces the Appointment of Geraldine Mcginty to the Board of Directors

New minor risk - Profitability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2026

New major risk - Revenue and earnings growth

4DMedical Limited, Annual General Meeting, Nov 02, 2023

Forecast to breakeven in 2026

Here's Why We're Not At All Concerned With 4DMedical's (ASX:4DX) Cash Burn Situation

First half 2023 earnings released: AU$0.06 loss per share (vs AU$0.04 loss in 1H 2022)

Consensus revenue estimates increase by 55%

We Think 4DMedical (ASX:4DX) Needs To Drive Business Growth Carefully

4DMedical Limited Appoints Matt Tucker as Senior Vice President of Business Development and Strategy

4Dmedical Unveils XV Scanner

Price target increased to AU$1.33

4DMedical Limited Releases CT LVAS in Australia

American Medical Association Current Procedural Terminology Editorial Panel Accepts 4Dmedical's Application for the Addition of A New Category III CPT Code

Is 4DMedical (ASX:4DX) In A Good Position To Deliver On Growth Plans?

4DMedical Limited, Annual General Meeting, Nov 03, 2022

4DMedical Limited Updates Vanderblit 'Burn Pit' Trial Hits Primary Endpoint

Consensus forecasts updated

Full year 2022 earnings: Revenues miss analyst expectations

We're Hopeful That 4DMedical (ASX:4DX) Will Use Its Cash Wisely

4Dmedical Limited Announces CFO Changes

High number of new directors

4DMedical Limited Appoints John Livingston as Role of Senior Strategist and Executive Director

4DMedical Limited Announces Clinical Trial Results Presented At Top US Lung Conference

High number of new directors

Price target decreased to AU$1.50

Price target decreased to AU$1.50

4DMedical Limited Announces Executive Changes

We Think 4DMedical (ASX:4DX) Can Afford To Drive Business Growth

High number of new directors

4DMedical Limited Announces First Commercial Scans with I-MED to Commence in December

Full year 2021 earnings released: AU$0.082 loss per share (vs AU$0.15 loss in FY 2020)

Full year 2021 earnings released

4D Medical Announces Undertaking Clinical Trial At the John Hopkins School of Medicine in Baltimore, USA

4DMedical Limited Commences XV LVAS Clinical Trial at Johns Hopkins School of Medicine, US

Here's Why We're Not Too Worried About 4DMedical's (ASX:4DX) Cash Burn Situation

4DMedical Limited Commences Patient Recruitment for VQ Trial

New 90-day low: AU$1.65

First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.04 loss in 1H 2020)

Is 4DMedical Limited's (ASX:4DX) Shareholder Ownership Skewed Towards Insiders?

4DMedical Limited Appoints Mr. Craige Pendleton-Browne as Chief Information Officer

New 90-day low: AU$2.07

4DMedical Limited Provides Update on Its First Clinical Pilot for XV Lung Ventilation Analysis Software

4DMedical Limited Completes First Commercial Scan in Australia

4Dmedical Limited Partners with University of Miami Health System to Establish the Functional Lung Imaging Research Program

4Dmedical Limited Receives TGA Approval for XV Lung Ventilation Analysis Software (XV LVAS)